Oxipit.ai

CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports.

The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia.

AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in this round.

AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans.

With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic.

Oxipit has conducted a retrospective validation study on ChestEye Quality performance. The study concludes that 1 in 552 (0.18%) chest X-ray studies reported by a radiologist include clinically significant diagnostic mistakes.

The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies.

Following the CE certification of the first autonomous AI medical imaging application ChestLink, researchers in Finland released a preprint of a study on the application performance on real-world clinical data.

The companies conducted a joint pilot study, where Oxipit's ChestEye Quality AI software is employed for improved pulmonary nodule detection. The software was deployed in two major primary care centers in Lithuania.

Oxipit was granted CE Class IIb certification for ChestLink autonomous AI imaging suite. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist.